Prophylaxis of neonatal jaundice with maternal antipyrine treatment.
A randomised controlled trial of antipyrine (phenazone) in the prophylaxis of neonatal jaundice was completed in 48 women. Treatment of mothers from the 38th week of pregnancy reduced neonatal plasma-bilirubin concentrations on the 4th day after birth by an average of 44%. Prophylaxis of neonatal jaundice merits a wider trial.
D000983:Antipyrine / Q000627:therapeutic use*; D001663:Bilirubin / Q000037:antagonists & inhibitors / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D005333:Fetus / Q000187:drug effects*; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000517:prevention & control*; D008297:Male; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011263:Pregnancy Trimester, Third; D011295:Prenatal Care; D011446:Prospective Studies; D012107:Research Design
D001663:Bilirubin; D000983:Antipyrine